Media Hub
Welcome to the CAR-TCR Summit Media Hub. Check in here for industry insights from our speakers, previous presentations and exclusive market insights.
Email info@hansonwade.com to submit content that you'd like to share here.
Exclusive Interview
Fabian Gerlinghaus
CEO & Co-Founder
Cellares
Advisory Board Interview
Exclusive interview with:
Joanna Brewer
Chief Scientific Officer
Adaptimmune Therapeutics
Pascal Touchon
President & Chief Executive Officer
Atara Biotherapeutics
Adrian Bot
Chief Scientific Officer & Executive Vice President of R&D
Capstan Therapeutics
Speaker Interview
We caught up with Milos Miljkovic, Chief Medical Officer, Cartesian Therapeutics at last year's CAR-TCR Summit. Here's what he had to say:
Milos Miljkovic
Chief Medical Officer
Cartesian Therapeutics
What made you decide to get involved in the 7th CAR-TCR Summit?
Cartesian Therapeutics has participated in several Hanson-Wade conferences in the past, and has had good experience. The topic of some of this year’s sessions, in particular moving CAR-T therapy beyond oncology, is particularly relevant to our current portfolio and future plans.
What would you consider to be the main trends in the CAR-TCR space at the moment?
Making CAR-T therapy more broadly available, both in terms of speed of access (lower manufacturing times and off-the-shelf approaches) and expanded indications.
Do you have any predictions for the space over the next year and beyond?
There will be more trials outside of oncology and more attempts to avoid apheresis and prolonged waiting periods.
What did you enjoy most about the meeting?
Having the opportunity to connect to suppliers and colleagues in person again.
Will you be joining the CAR-TCR Summit again next year if possible?
Yes, of course.
Previous Presentations
Fulfilling the Promise of
T Cell Therapy
Deyaa Adib
Chief Medical Officer
Triumvira Immunologics
Vein to Vein - Supplier Management for Autologous CAR-Ts
Edward Armstrong
Senior Director Quality
Mustang Bio
Archetypes of
CMC Excellence
Michael Lehmicke
Vice President, Science & Industry Affairs
Alliance for Regenerative Medicine
Can Precision Reimbursement Innovation Match Precision Oncology Therapeutics Advances?
Mark Trusheim
Strategic Director
NEWDIGS
Cell & Gene Ebook
Scaling Cell & Gene Therapies
Because scale up and scale out are significant to everyone in the cell and gene sector, CAR-TCR Summit media partners Cell & Gene have curated insightful editorial that addresses the most important aspects of scalability in the cell and gene therapy space.